Skip Nav Destination
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group
Issue Archive
Table of Contents
BLOOD COMMENTARIES
BLOOD SPOTLIGHT
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Clinical Trials & Observations
HOW I TREAT
HEMATOPOIESIS AND STEM CELLS
Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal
Mairi S. Shepherd,Juan Li,Nicola K. Wilson,Caroline A. Oedekoven,Jiangbing Li,Miriam Belmonte,Juergen Fink,Janine C. M. Prick,Dean C. Pask,Tina L. Hamilton,Dirk Loeffler,Anjana Rao,Timm Schröder,Berthold Göttgens,Anthony R. Green,David G. Kent
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
Clinical Trials & Observations
John Rossi,Patrick Paczkowski,Yueh-Wei Shen,Kevin Morse,Brianna Flynn,Alaina Kaiser,Colin Ng,Kyle Gallatin,Tom Cain,Rong Fan,Sean Mackay,James R. Heath,Steven A. Rosenberg,James N. Kochenderfer,Jing Zhou,Adrian Bot
LYMPHOID NEOPLASIA
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group
Clinical Trials & Observations
Kathryn G. Roberts,Shalini C. Reshmi,Richard C. Harvey,I-Ming Chen,Kinnari Patel,Eileen Stonerock,Heather Jenkins,Yunfeng Dai,Marc Valentine,Zhaohui Gu,Yaqi Zhao,Jinghui Zhang,Debbie Payne-Turner,Meenakshi Devidas,Nyla A. Heerema,Andrew J. Carroll,Elizabeth A. Raetz,Michael J. Borowitz,Brent L. Wood,Leonard A. Mattano, Jr,Kelly W. Maloney,William L. Carroll,Mignon L. Loh,Cheryl L. Willman,Julie M. Gastier-Foster,Charles G. Mullighan,Stephen P. Hunger
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment
Fathima Zumla Cader,Ron C. J. Schackmann,Xihao Hu,Kirsty Wienand,Robert Redd,Bjoern Chapuy,Jing Ouyang,Nicole Paul,Evisa Gjini,Mikel Lipschitz,Philippe Armand,David Wu,Jonathan R. Fromm,Donna Neuberg,X. Shirley Liu,Scott J. Rodig,Margaret A. Shipp
MYELOID NEOPLASIA
CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia
Huacheng Luo,Fei Wang,Jie Zha,Haoli Li,Bowen Yan,Qinghua Du,Fengchun Yang,Amin Sobh,Christopher Vulpe,Leylah Drusbosky,Christopher Cogle,Iouri Chepelev,Bing Xu,Stephen D. Nimer,Jonathan Licht,Yi Qiu,Baoan Chen,Mingjiang Xu,Suming Huang
THROMBOSIS AND HEMOSTASIS
LETTERS TO BLOOD
Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life
Sarah Huet,Etienne Paubelle,Camille Lours,Beatrice Grange,Lucien Courtois,Kaddour Chabane,Carole Charlot,Isabelle Mosnier,Thomas Simonet,Sandrine Hayette,Isabelle Tigaud,Xavier Thomas,Gilles Salles,Fabien Subtil,Pierre Sujobert
BLOOD WORK
ERRATUM
-
Cover Image
Cover Image
Anti-hCD45 immunohistochemically stained spleen section from a CBS7/9+/− MLL-rearranged MOLM13 cell–transplanted mouse model of acute myeloid leukemia (AML). The reduction of the CD45+ human AML cell chimerism (brown cells) indicates that CCCTC-binding factor (CTCF) chromatin boundaries may be novel therapeutic targets for AML treatment. See the article by Luo et al on page 837.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals